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Abstract
The Framingham Heart Study, founded in 1948 to examine the epidemiology of cardiovascular
disease in a small town outside of Boston, has become the worldwide standard for cardiovascular
epidemiology. It is among the longest running, most comprehensively characterized multi-
generational studies in the world. Such seminal findings as the effects of smoking and high
cholesterol on heart disease came from the Framingham Heart Study. At the time of publication
these were novel cardiovascular disease (CVD) risk factors, now they are the basis of treatment
and prevention in the US. Is the Framingham study now on it's way to becoming the gold standard
for genetic epidemiology of CVD? Will the novel genetic findings of today become the health care
standards of tomorrow? The accompanying articles summarizing the results of genome-wide
association studies (GWAS) give the reader a first glimpse into the possibilities.
The Framingham Heart Study, founded in 1948 to exam-
ine the epidemiology of cardiovascular disease in a small
town outside of Boston, has become the worldwide stand-
ard for cardiovascular epidemiology [1,2]. It is among the
longest running, most comprehensively characterized
multi-generational studies in the world. Such seminal
findings as the effects of smoking and high cholesterol on
heart disease came from the Framingham Heart Study
[3,4]. At the time of publication these were novel cardio-
vascular disease (CVD) risk factors, now they are the basis
of treatment and prevention in the US. Is the Framingham
study now on its way to becoming the gold standard for
genetic epidemiology of CVD? Will the novel genetic find-
ings of today become the health care standards of tomor-
row? The accompanying articles summarizing the results
of genome-wide association studies (GWAS) give the
reader a first glimpse into the possibilities.
The strength of the Framingham Study has always been
and will always be their extensive, well-characterized, lon-
gitudinal phenotypes. In an era of human genetics where
speed is of the essence, such phenotypes are hard to come
by. The recent explosion of genetic information available
and low-cost genotyping technology has allowed for
extensive hypothesis-free genome-wide interrogation
[5,6]. Genome-wide association studies (GWAS) generally
type 500,000 or more SNPs on approximately 1,000 or
more individuals. Typing of an extensive number of gen-
otypes increases the power to detect variants of small to
moderate effect in a relatively small sample. However, it
does create a multiple testing problem, especially in stud-
ies such as Framingham where there are hundreds of
thousands of genotypes measured in thousands of indi-
viduals and associated with thousands of phenotypes. A
major challenge in this GWAS endeavor will be to separate
the true associations from the false positives. This is where
the extensive phenotyping will be critical. Only through
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and genetic associations can one hope to find a hint of the
underlying biological pathways leading to disease risk.
This is where Framingham can become the gold standard.
Replication will be critical in determining which associa-
tions are real as we begin to see the results of multiple
GWAS. A paper was recently published in Nature [7] pro-
viding guidelines for what constitutes replication. The
authors provide an outline of points that should be
addressed in an initial GWAS report; these points provide
the necessary information for others to interpret and rep-
licate the findings. The Framingham data meet all of these
criteria, plus all data and results are provided to the scien-
tific community through a full disclosure web-based
resource. This enables exact replication of the Framing-
ham findings or use of the Framingham data to replicate
other GWAS findings.
The data presented in the accompanying papers are not
optimal. The reports are based on a preliminary GWAS
with a lower SNP density (100,000 SNPs) and a less accu-
rate allele calling algorithm (Dynamic modeling or DM)
than is the standard today [8] typed in a subset (1,345) of
the Framingham cohort. However, the genotyping and
allele calling algorithm were state of the art at the time
they were performed and the subset consists of families,
which broaden the analytic approaches that can be used.
Recently genotyping of 550,000 SNPs was completed in
the entire Framingham cohort (N = 9,300) [9]. Even with
the limitations of the 100 K analysis the results and their
implications are noteworthy and will provide informa-
tion useful in interpretation of the results from the 500 K
analysis.
First, because the GWAS was performed in families, results
from linkage and association can be compared. Most
human geneticists are abandoning linkage in favor of the
latest technology-driven methods. However, linkage can
provide valuable information to aid in differentiating
between real associations and false positives. It was
encouraging to see that two of the inflammatory markers
(MCP1 concentration and CRP levels) showed concord-
ant linkage and association peaks [9]. However, there
were many cases where significant association was not
accompanied by significant linkage. This is expected
because of the difference in power to detect genes of small
to moderate effect between the methods, and the rate of
false positives.
Second, because Framingham is a cohort without disease-
based ascertainment, a multitude of phenotypes can be
investigated. Many of these phenotypes are correlated.
This provides the opportunity to investigate pleiotropy
and to begin to decipher the genetic architecture of com-
plex diseases such as CVD. The Framingham investigators
performed a first pass look at this question. They looked
for overlap among the top 500 SNPs associated with phe-
notypes across three "working groups": glycemic/diabetes
phenotypes, lipid phenotypes and obesity phenotypes.
Eleven SNPs were found in more than one group, but
none of these were found in all three [10-12]. These
results provide intriguing areas to further investigate by
actually modeling the pleiotropic effect of these variants.
Third, I think it is important to note that, despite the lim-
itations of these data, the Framingham investigators repli-
cated several well-established candidate gene
associations. Among these were SNPs in the TCF7L2 gene
and diabetes [10], SNPs in the factor VII gene and CRP
gene with their respective gene products [9,13] and SNPs
in the AGT gene and blood pressure [14]. In addition, sev-
eral associations found in recent GWASs were replicated
in the Framingham sample. Most notably is the associa-
tion of coronary heart disease, CVD and coronary artery
calcium [15,16] with the same region of 9p recently
reported to be associated with myocardial infarction by
Helgadottir et al. [17] and McPherson et al. [18].
The analysis of such a large volume of data and presenta-
tion of results is a daunting task. The Framingham inves-
tigators have done a commendable job in getting the
results out and providing the data for other investigators
to use. In the process they have entered the "gold rush" to
stake claims on GWAS results [19]. Although this initial
task was daunting, what lies ahead is even more so.
Results such as these as they stand are valuable in their
own right. However, they are invaluable when interpreted
within the context of other genetic and environmental risk
factors. It is in this next step of delving beyond the p-val-
ues where Framingham can set the gold standard. The
Framingham Heart Study has meticulously collected the
information necessary to decipher the genetic and envi-
ronmental risk factors for cardiovascular disease and they
have the expertise to do so. Only through such a meticu-
lous approach can we provide an integrated, holistic view
of health and disease. The world wide scientific commu-
nity will be looking to the Framingham Heart Study to set
the gold standard once again, this time in the genomic era.
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